Home
INDP
INDP News

Latest Indaptus Therapeutics Inc. (INDP) News on August 3, 2025

Indaptus Therapeutics Announces Reverse Stock Split

GlobeNewswire

a month ago

Indaptus Therapeutics Announces Reverse Stock Split

Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants

GlobeNewswire

2 months ago

Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants

Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

GlobeNewswire

2 months ago

Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire

3 months ago

Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit

GlobeNewswire

3 months ago

Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

GlobeNewswire

4 months ago

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

GlobeNewswire

4 months ago

Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

GlobeNewswire

5 months ago

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

GlobeNewswire

5 months ago

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Registration Is Now Open For Tribe Public’s Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025

GlobeNewswire

5 months ago

Registration Is Now Open For Tribe Public’s Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

GlobeNewswire

5 months ago

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit

GlobeNewswire

5 months ago

Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

GlobeNewswire

6 months ago

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules

GlobeNewswire

7 months ago

Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

GlobeNewswire

7 months ago

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

GlobeNewswire

8 months ago

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

9 months ago

Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

GlobeNewswire

9 months ago

Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

GlobeNewswire

9 months ago

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

Indaptus Therapeutics to Present at Two Upcoming Investor Conferences

GlobeNewswire

9 months ago

Indaptus Therapeutics to Present at Two Upcoming Investor Conferences

Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations

GlobeNewswire

9 months ago

Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations

Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data

GlobeNewswire

10 months ago

Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data

Indaptus Therapeutics Founder and Chief Scientific Officer to Speak on Lumanity Webinar about the Future of Innate Immunity in Cancer Immunotherapy

GlobeNewswire

10 months ago

Indaptus Therapeutics Founder and Chief Scientific Officer to Speak on Lumanity Webinar about the Future of Innate Immunity in Cancer Immunotherapy

Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

GlobeNewswire

10 months ago

Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses

GlobeNewswire

a year ago

Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses

Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire

a year ago

Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Indaptus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

Indaptus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Insider Buyers Lose US$41k As Indaptus Therapeutics Sheds US$1.2m

Simply Wall St.

a year ago

Insider Buyers Lose US$41k As Indaptus Therapeutics Sheds US$1.2m

Indaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private Placement

GlobeNewswire

a year ago

Indaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private Placement

Indaptus Therapeutics to Present Positive Data on Lead Product Candidate, Decoy20, at STING & TLR-Targeted Therapies Summit

GlobeNewswire

a year ago

Indaptus Therapeutics to Present Positive Data on Lead Product Candidate, Decoy20, at STING & TLR-Targeted Therapies Summit

Lotto 6/49 - $64 million up for grabs in the next draw!

CNW Group

a year ago

Lotto 6/49 - $64 million up for grabs in the next draw!

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Simply Wall St.

a year ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North

AFP

a year ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Simply Wall St.

a year ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Barrons.com

a year ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

Simply Wall St.

a year ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Simply Wall St.

a year ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Trip.com Reveals 2024 Trip.Best Global and Asia 100 Rankings

CNW Group

a year ago

Trip.com Reveals 2024 Trip.Best Global and Asia 100 Rankings

The Company Behind Mounjaro and Zepbound Is Sponsoring Caitlin Clark. Should You Buy the Stock?

Motley Fool

a year ago

The Company Behind Mounjaro and Zepbound Is Sponsoring Caitlin Clark. Should You Buy the Stock?

3 Capital Markets Stocks to Buy Hand Over Fist in June

Motley Fool

a year ago

3 Capital Markets Stocks to Buy Hand Over Fist in June

3 Types of Homes To Buy During Summer 2024 To Get Rich

GOBankingRates

a year ago

3 Types of Homes To Buy During Summer 2024 To Get Rich

4 Ways the Upper Class Handles Inflation That the Middle Class Could Learn From

GOBankingRates

a year ago

4 Ways the Upper Class Handles Inflation That the Middle Class Could Learn From

Gaming laptops are being left behind

Digital Trends

a year ago

Gaming laptops are being left behind

I’m a Financial Advisor: Here Are the 6 Worst Secrets You Can Keep from Me

GOBankingRates

a year ago

I’m a Financial Advisor: Here Are the 6 Worst Secrets You Can Keep from Me

What a Comfortable Retirement Will Cost You in 61 of the Largest US Cities

GOBankingRates

a year ago

What a Comfortable Retirement Will Cost You in 61 of the Largest US Cities

Getting smarter: FIA Launches 3-Day Smart Driving Challenge in Samarkand, Powered by Greater Than

PR Newswire

a year ago

Getting smarter: FIA Launches 3-Day Smart Driving Challenge in Samarkand, Powered by Greater Than

3 Major Product Releases at 3Shape Discover Event

PR Newswire

a year ago

3 Major Product Releases at 3Shape Discover Event

Fiber Optic Sensors Global Market Forecast & Analysis 2023-2033: Global Fiber Optic Sensors Market to Reach $605.4 Million by 2032 with a CAGR of 6.2%

GlobeNewswire

a year ago

Fiber Optic Sensors Global Market Forecast & Analysis 2023-2033: Global Fiber Optic Sensors Market to Reach $605.4 Million by 2032 with a CAGR of 6.2%

Exploring SEHK Growth Companies With High Insider Ownership: BYD Leads The Way

Simply Wall St.

a year ago

Exploring SEHK Growth Companies With High Insider Ownership: BYD Leads The Way

Business Wire

a year ago

Net Asset Value(s)

Irish, Czechs hold EU vote after Dutch far-right gains

AFP

a year ago

Irish, Czechs hold EU vote after Dutch far-right gains

Trade the Nvidia Stock Split? The Tried-and-True Method to Make the Best Profits on the Leading AI Stock

Motley Fool

a year ago

Trade the Nvidia Stock Split? The Tried-and-True Method to Make the Best Profits on the Leading AI Stock

GPRC5D Targeting Drugs Market Opportunity and Clinical Trials Insight 2024: Insight on 15+ Drugs in Clinical Trials

GlobeNewswire

a year ago

GPRC5D Targeting Drugs Market Opportunity and Clinical Trials Insight 2024: Insight on 15+ Drugs in Clinical Trials

Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference

GlobeNewswire

a year ago

Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference

Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20

GlobeNewswire

a year ago

Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20

Indaptus Therapeutics to Present at the Jefferies Global Healthcare Conference

GlobeNewswire

a year ago

Indaptus Therapeutics to Present at the Jefferies Global Healthcare Conference

Indaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual Meeting

GlobeNewswire

a year ago

Indaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual Meeting

Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors

GlobeNewswire

a year ago

Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid Tumors

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

GlobeNewswire

a year ago

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference

GlobeNewswire

a year ago

Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

GlobeNewswire

a year ago

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024

GlobeNewswire

a year ago

Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort

GlobeNewswire

a year ago

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort

Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference

GlobeNewswire

a year ago

Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference

Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

GlobeNewswire

a year ago

Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

Advanced Emissions Solutions Completes Rebrand as Arq and Will Ring NASDAQ Opening Bell on February 1, 2024

GlobeNewswire

2 years ago

Advanced Emissions Solutions Completes Rebrand as Arq and Will Ring NASDAQ Opening Bell on February 1, 2024

Rhinebeck Bancorp, Inc. Reports Results for the Quarter and Year Ended December 31, 2023

ACCESSWIRE

2 years ago

Rhinebeck Bancorp, Inc. Reports Results for the Quarter and Year Ended December 31, 2023

Advanced Emissions Solutions Signs Contract for Construction of Granular Activated Carbon Expansion at Red River Plant with Wieland

GlobeNewswire

2 years ago

Advanced Emissions Solutions Signs Contract for Construction of Granular Activated Carbon Expansion at Red River Plant with Wieland

Yunhong Green CTI Announces Formation of New China Based Subsidiary, Yunhong Technology Industry (Hubei) Co., Ltd

ACCESSWIRE

2 years ago

Yunhong Green CTI Announces Formation of New China Based Subsidiary, Yunhong Technology Industry (Hubei) Co., Ltd

GlobeNewswire

2 years ago

Abpro Announces Filing of Registration Statement on Form S-4 in Connection with Business Combination Agreement with Atlantic Coastal Acquisition Corp. II

Business Wire

2 years ago

Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Evaluating the Safety of Renuvion® Following Liposuction in Multiple Areas of the Body

Home Federal Bancorp, Inc. of Louisiana Declares Quarterly Cash Dividend

GlobeNewswire

2 years ago

Home Federal Bancorp, Inc. of Louisiana Declares Quarterly Cash Dividend

Phoenix Issues Preliminary Guidance Following the Purchase of Proterra's Transit Business

ACCESSWIRE

2 years ago

Phoenix Issues Preliminary Guidance Following the Purchase of Proterra's Transit Business

Golden Matrix Reports Fiscal 2023 Financial Results With Record Revenues of $44.2 Million

NewMediaWire

2 years ago

Golden Matrix Reports Fiscal 2023 Financial Results With Record Revenues of $44.2 Million

Sidoti Events, LLC's Virtual January Micro-Cap Conference

ACCESSWIRE

2 years ago

Sidoti Events, LLC's Virtual January Micro-Cap Conference

ClearPoint Neuro Announces FDA Clearance for SmartFrame OR™ Stereotactic System

GlobeNewswire

2 years ago

ClearPoint Neuro Announces FDA Clearance for SmartFrame OR™ Stereotactic System

Advanced Emissions Solutions to Attend the Sidoti Micro-Cap Conference on January 17th and 18th

GlobeNewswire

2 years ago

Advanced Emissions Solutions to Attend the Sidoti Micro-Cap Conference on January 17th and 18th

Newsfile

2 years ago

Snow Lake Lithium CEO Update to Shareholders

Q3 Rundown: Molson Coors (NYSE:TAP) Vs Other Beverages and Alcohol Stocks

StockStory

2 years ago

Q3 Rundown: Molson Coors (NYSE:TAP) Vs Other Beverages and Alcohol Stocks

Comstock Metals Receives Air Quality Permit from the State of Nevada

GlobeNewswire

2 years ago

Comstock Metals Receives Air Quality Permit from the State of Nevada

Business Wire

2 years ago

Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2023 Revenue Results

Elevation Oncology Announces Program Updates and Upcoming 2024 Milestones

PR Newswire

2 years ago

Elevation Oncology Announces Program Updates and Upcoming 2024 Milestones

Catch the Future in Action: LeddarTech Unveils Its Award-Winning LeddarVision ADAS Products and Technology at CES Las Vegas 2024

CNW Group

2 years ago

Catch the Future in Action: LeddarTech Unveils Its Award-Winning LeddarVision ADAS Products and Technology at CES Las Vegas 2024

European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology

GlobeNewswire

2 years ago

European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology

Assertio Holdings, Inc. Announces Leadership Transition

GlobeNewswire

2 years ago

Assertio Holdings, Inc. Announces Leadership Transition

Comstock (LODE) Executes First Commercial Biorefinery Deal

Zacks

2 years ago

Comstock (LODE) Executes First Commercial Biorefinery Deal

5 Top Energy Growth Stocks That You Need to Buy for 2024

Zacks

2 years ago

5 Top Energy Growth Stocks That You Need to Buy for 2024

Vital Energy (VTLE) in $55M Deal to Enhance Permian Presence

Zacks

2 years ago

Vital Energy (VTLE) in $55M Deal to Enhance Permian Presence

Snail., Inc Unveils Everlasting Winter Wonderland Mod For ARK: Survival Ascended

GlobeNewswire

2 years ago

Snail., Inc Unveils Everlasting Winter Wonderland Mod For ARK: Survival Ascended

Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido® is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists

GlobeNewswire

2 years ago

Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido® is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists

Snow Lake Expands Its Lithium Portfolio with Mineral Claims Next to the Tanco Mine

Newsfile

2 years ago

Snow Lake Expands Its Lithium Portfolio with Mineral Claims Next to the Tanco Mine

3 Growth Stocks That Can Double in 2024

InvestorPlace

2 years ago

3 Growth Stocks That Can Double in 2024

Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis

GlobeNewswire

2 years ago

Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis

Genasys Independent Director Acquires 13% More Stock

Simply Wall St.

2 years ago

Genasys Independent Director Acquires 13% More Stock

InvestorPlace

2 years ago

AMC Stock: This Dog With Fleas Just Won’t Die. Should You Buy? NO.

17 Education & Technology Group Inc. Announces Plan to Implement ADS Ratio Change

GlobeNewswire

2 years ago

17 Education & Technology Group Inc. Announces Plan to Implement ADS Ratio Change

Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential

InvestorPlace

2 years ago

Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential

Share on Social Networks: